Alpha Tau Medical Ltd ((DRTS)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Alpha Tau Medical Ltd is conducting a clinical study titled ‘A Study to Assess the Safety of Intratumoral Diffusing Alpha Radiation Emitters With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer.’ The study aims to evaluate the safety and efficacy of combining Alpha DaRT therapy with chemotherapy in treating pancreatic cancer. This multi-center study will enroll 30 participants to assess the treatment’s impact on safety, survival rates, pain control, and surgical resection rates.
The intervention being tested is the Diffusing Alpha Radiation Emitters Therapy (DaRT), a device designed to deliver targeted radiation therapy directly into tumors. This method aims to enhance the effectiveness of chemotherapy in treating pancreatic cancer.
The study is interventional, with a non-randomized, parallel assignment model. It is open-label, meaning no masking is involved, and its primary purpose is treatment. Participants are divided into two cohorts based on their cancer stage: locally advanced or metastatic.
The study began on June 17, 2025, with primary completion and estimated completion dates yet to be announced. The last update was submitted on July 13, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This study could significantly impact Alpha Tau Medical’s stock performance, as positive results may boost investor confidence and position the company as a leader in innovative cancer treatments. Competitors in the oncology sector will likely monitor these developments closely.
The study is ongoing, with further details available on the ClinicalTrials portal.